%20--%3e%3c!DOCTYPE%20svg%20PUBLIC%20'-//W3C//DTD%20SVG%201.1//EN'%20'http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd'%20[%20%3c!ENTITY%20st0%20'fill:%23267E9A;'%3e%3c!ENTITY%20st1%20'fill:%2378C9DA;'%3e%3c!ENTITY%20st2%20'fill:%23FFFFFF;'%3e%3c!ENTITY%20st3%20'fill:%23085580;'%3e%3c!ENTITY%20st4%20'fill:%2386C34A;'%3e%3c!ENTITY%20st5%20'fill:%232FBBCC;'%3e%3c!ENTITY%20st6%20'fill:%234C6F90;'%3e%3c!ENTITY%20st7%20'fill:%23194670;'%3e%3c!ENTITY%20st8%20'fill:%2307557E;'%3e%3c!ENTITY%20st9%20'fill:%23516E89;'%3e%20]%3e%3csvg%20version='1.1'%20id='Layer_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%2032%2032'%20style='enable-background:new%200%200%2032%2032;'%20xml:space='preserve'%3e%3cg%3e%3cg%3e%3crect%20x='10.3'%20y='14'%20style='&st5;'%20width='5'%20height='4.4'/%3e%3crect%20x='10.3'%20y='12'%20style='&st5;'%20width='11.4'%20height='1'/%3e%3crect%20x='16.4'%20y='14'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='15.8'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='17.5'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='19.3'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='10.3'%20y='19.3'%20style='&st5;'%20width='5'%20height='0.9'/%3e%3cg%3e%3cpath%20style='&st5;'%20d='M22.6,22.3H9.4c-0.6,0-1.2-0.5-1.2-1.2v-10c0-0.6,0.5-1.2,1.2-1.2h13.1c0.6,0,1.2,0.5,1.2,1.2v10%20C23.7,21.7,23.2,22.3,22.6,22.3z%20M9.4,10.8c-0.1,0-0.3,0.1-0.3,0.3v10c0,0.1,0.1,0.3,0.3,0.3h13.1c0.1,0,0.3-0.1,0.3-0.3v-10%20c0-0.1-0.1-0.3-0.3-0.3H9.4z'/%3e%3c/g%3e%3c/g%3e%3cpath%20style='&st5;'%20d='M16,30.2C8.2,30.2,1.8,23.8,1.8,16S8.2,1.8,16,1.8S30.2,8.2,30.2,16S23.8,30.2,16,30.2z%20M16,2.8%20C8.7,2.8,2.8,8.7,2.8,16S8.7,29.2,16,29.2S29.2,23.3,29.2,16S23.3,2.8,16,2.8z'/%3e%3c/g%3e%3c/svg%3e)
Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Recently Added News
10/30/2026
BreakingClinical TrialMyopiaRegulation
US FDA Advisory Panel Meets to Review Sydnexis’ Rejected Myopia Drop, Hear Public Comments
The US FDA Dermatologic and Ophthalmic Drugs Advisory Committee held a meeting and open public hearing on Oct. 30 in Silver Spring, Maryland, to review the new drug application (NDA) for Sydnexis’ ...
10/30/2026
BreakingCataractDealsIndiaRetinaSurgical
Appasamy Acquires Ruck and its Qube Pro Dual-Function Platform
India’s Appasamy Associates, a portfolio company of Warburg Pincus, reported Oct. 22 that it had acquired German company Ruck, manufacturer of ophthalmic surgical products for both the front and ba...
10/30/2026
BreakingCornealDry EyeGlaucomaIOLLaserPremiumPresbyopiaRetinaRevenue
Q3-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Glaukos, Novartis, Lumibird, and Lenz
Bausch + Lomb reported Oct. 28 that its Q3-2026 revenue totaled $1.4 billion, a 7 percent increase (+8 percent cc) from $1.3 billion in Q3-2025. Ophthalmic pharmaceuticals segment revenue was $367 ...
10/30/2026
BreakingClinical TrialGene TherapyRegulationRetina
US FDA Gives Green Light to Trial of Opus’ Gene Therapy for RDH12-LCA
Opus Genetics announced on Oct. 21 that the US FDA had signed off on its investigational new drug application, allowing the company to proceed with a clinical trial of OPGx-RDH12, a gene therapy ca...
10/30/2026
BreakingDry EyeStudy
Researchers Develop New Standardized Grading System for MGD
A study published Oct. 6 in Clinical Optometry introduces the Meibomian Gland Composite Score (MGCS)—a standardized grading system that could help clinicians more precisely track meibomian gland dy...
10/30/2026
BreakingDiagnosticLaserRetina
Volk Launches ClearField Pro Lens for Retinal Exams, Laser Treatment
Volk Optical announced Oct. 7 the launch of ClearField Pro, a new ophthalmic lens designed for retinal examination and laser indirect ophthalmoscopy. The lens’ advanced coating provides up to 77 pe...
10/30/2026
BreakingDealsOcular CancerOcular Surface
Visara Gains Exclusive Option to Acquire Candidate for Ocular Surface Squamous Neoplasia
Visara, the ophthalmology subsidiary of NovaBridge Biosciences, announced Oct. 20 that it had gained an exclusive option to acquire worldwide rights to YOLO Immune’s YOL104-2, a candidate for ocula...
10/30/2026
BreakingDiagnosticDigitalGlaucomaPerimetry
RadiusXR, Topcon Introduce InspirePro Wearable Perimeter
RadiusXR and strategic partner Topcon Healthcare introduced the lightweight, wearable InspirePro perimeter at the American Academy of Ophthalmology’s 2026 meeting, held Oct. 10-12 in New Orleans, L...
10/30/2026
BreakingCornealDry EyeRegulation
Stuart Submits IND Amendment to US FDA for Trial of ST-100 in Corneal Wound Healing
Stuart Therapeutics announced Oct. 9 that it had submitted an investigational new drug application (IND) amendment to the US FDA to study its lead candidate, ST-100 (vezocolmitide) eye drops, in co...
10/30/2026
BreakingCell TherapyEuropeRegulationRetina
EMA Grants Orphan Drug Status to BlueRock’s IRD Cell Therapy Candidate
Bayer subsidiary BlueRock Therapeutics announced Sept. 30 that its investigational cell therapy, lemiretprocel (OpCT-001), had received orphan drug designation from the European Medicines Agency. T...
10/23/2026
BreakingDealsRetina
Alcon Acquires Neurotech and its MacTel Treatment Encelto for $550 Million
Alcon announced Oct. 20 that it had acquired Neurotech Pharmaceuticals, maker of Encelto for macular telangiectasia Type 2 (MacTel), for $550 million. Alcon said that it might be required to make a...
10/23/2026
BreakingCataractIOLPharmaPremiumRetinaRevenueSurgical
Q3-2026 Ophthalmic Revenue Roundup for Roche and J&J Vision
Swiss company Roche reported Oct. 22 that Q3-2026 Vabysmo sales were CHF 1.1 billion ($1.4 billion, converted for Sept. 20, 2026) a 13 percent increase over CHF 996 million in Q3-2025. US Vabysmo s...
Past News Stories
10/23/2026
BreakingPharmaRegulation
US FDA Approves Alcon’s Brytly 12-Hour Redness Reliever Eye Drops
Alcon announced Oct. 16 that the US FDA had approved Brytly (apraclonidine 0.125%), a redness relieving eye drop. The company said one drop of Brytly works in one minute and lasts up to 12 hours, o...
10/21/2026
ESCRSIOLLaserMeetingNewsletterRefractiveSurgical
Lens-vs.-Laser Debate Heats Up at ESCRS Congress as New Refractive Technologies are Launched
The long-running debate between laser- and lens-based refractive surgery intensified at the 2026 ESCRS congress in London, where new product launches and packed scientific sessions underscored a ma...
10/23/2026
BreakingPharmaPresbyopia
US FDA Approves Ryzumvi from Opus and Viatris for Presbyopia
Commercial partners Viatris and Opus Genetics reported Oct. 16 that the US FDA had approved Ryzumvi (phentolamine ophthalmic solution 0.75%) as a treatment for presbyopia. The milestone marks the f...
10/23/2026
BreakingClinical TrialIndustryPharmaRetina
EyePoint to Slash Workforce, End Pivotal Wet AMD Trials After Second Miss for Duravyu
EyePoint announced Oct. 19 that it would cut its workforce by 53 percent and end the Phase III trials for Duravyu in wet age-related macular degeneration (AMD) early after the LUCIA study failed to...
10/23/2026
BreakingPharmaRegulationRetina
Belite Files for Approval of Oral Stargardt Candidate in Singapore, UK, Switzerland
Belite Bio announced Oct. 14 that it had filed for marketing approval for its oral Stargardt treatment candidate, tinlarebant, in three countries—Singapore, the UK, and Switzerland—under those nati...
10/23/2026
BreakingDiagnosticPerimetry
Haag-Streit and Marco Lombart Launch Octopus 910 Perimeter in the US
Haag-Streit USA and distributor Marco Lombart reported Oct. 10 that they had launched the Octopus 910 perimeter in the US. A global launch is set for January 2027. The full-field projection perimet...
10/21/2026
AIDealsDiagnosticESCRSMeetingNewsletter
Futures Forum Highlights Higher Investment Bar, Looks at AI Concerns
A common theme at the 2026 Ophthalmology Futures European Forum was that capital and innovation remain available, but the bar for both has risen. The forum was held Sept. 10 at Glaziers Hall on the...
10/21/2026
Dry EyeNewsletterPharmaRevenue
Miticides to Treat Dry Eye Climbing Toward $1 Billion in Annual Sales
Tarsus Pharmaceuticals is behind the rapid growth of the miticide category of dry-eye related pharmaceuticals in the US. Market Scope expects US sales in the miticide category to soon exceed $1 bil...
10/21/2026
DealsGene TherapyNewsletterRetina
Gene Therapy Reclaims Top Spot in Ophthalmic Fundraising
Ophthalmic gene therapy fundraising has reached nearly $1.3 billion in 2026, propelled by major investments in Beacon Therapeutics, Regenxbio, and MeiraGTx. Beacon closed a Series C round in Januar...
10/21/2026
DealsIOLNewsletterRetina
Saunders Departs Bausch + Lomb, as Chairman Appio Takes Over
Bausch + Lomb announced Oct. 12 that CEO Brent Saunders would leave the company immediately, with chairman Thomas Appio taking over as interim CEO. Appio also is CEO of Bausch Health. Saunders had ...
10/21/2026
IOLNewsletterRegulation
Rayner Launches RayOne Galaxy IOL in US after Receiving FDA Approval
UK-based Rayner announced Sept. 24 that its RayOne Galaxy and RayOne Galaxy Toric IOLs were commercially available in the US after the lenses gained FDA approval. The Galaxy is the first-ever spira...
10/21/2026
AcquisitionsDealsNewsletterRetina
Alcon Acquires Neurotech and its MacTel Treatment Encelto for $550 Million
Alcon announced Oct. 20 that it had acquired Neurotech Pharmaceuticals, maker of Encelto for macular telangiectasia Type 2 (MacTel), for $550 million. Alcon said that it might be required to make a...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.